Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Janssen Research & Development, LLC
Cetrelimab is a monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with the ligands PD-L1 and PD-L2. By preventing PD-1-mediated inhibitory signaling, it promotes T-cell activation and T-cell responses against tumor cells. It is being studied in neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07525141 | Phase 1 | Neoplasms | Recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neoplasms
Updated Nov 15, 2026. Something wrong or missing? Report it on the JNJ page.
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →